Separator

Digi-Prex Subsidiary Good Health Clinic rises $5.2 million from Khosla Ventures & Others

Separator
Good Health Clinic (GHC), a subsidiary of Hyderabad-based healthtech startup Digi-Prex, has raised $5.2 million from angel investors including Khosla Ventures, Quiet Capital, W Health Ventures, and Weekend Fund.

GHC is a clinic for men. The startup have good health products for men who don't fit into long-held stereotypes - under the brand 'Mars.' The products are researched to bring the best ingredients to improve men's health, are made with high-quality ingredients, and are packaged for men who identify with the new modern avatar of men.

The startup offers a full-stack solution for patients suffering from conditions such as hair loss, sexual health, weight loss, skincare, and so on. The products were first introduced in January of this year, with the hairfall category; since then, the startup has rapidly expanded into new categories.
The fund will be used by the startup to invest in new categories, build out a team, and build a strong infrastructure.

"We have gotten off to an exciting start and want to keep building on our momentum. Our plan is to expand into more categories that solve similar common health problems for people from the comfort of their home. We plan to improve the availability of information around these conditions, allowing people to really understand what is causing their conditions, and why and how our solution will help them," says Samarth Sindhi, Founder, GHC.

He goes on to say that the startup's goal is to provide a full-stack solution for patient problems. GHC offers unlimited free consultations with their team of experts, and a course of treatment is recommended for each patient's condition.

Previously, parent company Digi-Prex raised $5.5 million in a seed round led by Khosla Ventures. Samarth, a Brown University mechanical engineering graduate, founded it in 2019. The startup was chosen to participate in Y Combinator's Demo Day in August 2019.

The healthcare market in India, which is currently booming, is expected to reach $372 billion by 2022. Other players in the medication delivery space include Practo, NetMeds, 1mg, and PharmEasy.